Cosmo Pharmaceuticals SA, a closely held developer of gastrointestinal products, has spun out around half of its subsidiary, Cassiopea SpA, on the SIX Swiss Stock Exchange, but the majority shareholders of Cosmo will remain majority shareholders of Cassiopea.
